Shobhaben Pratapbhai Patel School of Pharmacy & Technology Management, SVKM's NMIMS, V.L. Mehta Road, Vile Parle (W), Mumbai, 400056, India.
Amity Institute of Pharmacy, Amity University, Panvel, Mumbai, Maharashtra, 410206, India.
Curr Radiopharm. 2024;17(2):148-162. doi: 10.2174/0118744710277275231112081003.
Radiopharmaceuticals are in the diagnosis and treatment of cancerous and noncancerous diseases, and a hope for optimistic effort in the field of nuclear medicine. They play a crucial role in clinical nuclear medicine by providing a tool to comprehend human disease and create efficient treatments. A detailed analysis is provided regarding the crux of molecular imaging including PET and SPECT overview for the detection of cancers. For a specified understanding of radiation therapy, topics include ranging from the selection of radionuclide to its development and manufacture, and dosage requirements to establishing the importance of I- 131 Radiotherapy in thyroid cancer. In this review, we also discussed the current state of the art of nuclear medicine in thyroid cancer, including the role of radioiodine (RAI) therapeutic scans in the diagnosis of differentiated thyroid cancer. In addition, we established a brief outlook into the current status of the research in thyroid cancer and discussed the future directions in this field.
放射性药物在癌症和非癌症疾病的诊断和治疗中发挥着重要作用，是核医学领域充满希望的努力方向。它们在临床核医学中发挥着关键作用，为理解人类疾病和创造有效治疗方法提供了工具。本文详细分析了分子成像的核心问题，包括正电子发射断层扫描（PET）和单光子发射计算机断层扫描（SPECT）在癌症检测中的概述。为了更具体地了解放射治疗，本文涵盖了从放射性核素的选择到其开发和制造，以及剂量要求，再到确立放射性碘（I-131）在甲状腺癌治疗中的重要性等方面的内容。在这篇综述中，我们还讨论了甲状腺癌的核医学的最新进展，包括放射性碘（RAI）治疗扫描在分化型甲状腺癌诊断中的作用。此外，我们还简要展望了甲状腺癌的研究现状，并讨论了该领域的未来发展方向。
